• Genetic Drug Sensitivity Testing, Simplified

    PGXL’s panel eases the management of pharmaceutical therapy to give physicians the whole picture, predicting how drugs will interact with each other and the patient’s genetics, in a single report. More

    Tubes 619

  • The Ability to Do More

    Researchers who need to add genetics to their trial design need a partner that brings more than testing capabilities to the table. PGXL’s scientists have participated in hundreds of trials, and no one knows more about incorporating genetics into clinical trials than we do. More

  • Single Cell Recovery and Characterization

    Genetic variation in tumors and circulating tumor cells can play a role in disease progression and treatment. PGXL’s exclusive single cell sorting and isolation provides molecular information at the level of individual cells.  More.

    Silicon Bio Art 619

About PGxl

PGXL is an internationally recognized pioneer in the application of pharmacogenetics to personalized medicine.  The company was founded in 2005 by Dr. Roland Valdes, Jr., and Dr. Mark W. Linder, researchers who are worldwide thought leaders in the science underlying personalized medicine. The lab is CLIA and CAP certified, and has been set-up to provide quick and accurate testing for both clinical use and research.

You can follow PGXL on Twitter @PGXLlabs


  • PGXL Adds NextGen Sequencing

    PGXL Technologies, which identifies and developes promising personalized medicine technologies, has validated and is now offering Next Generation Sequencing services. While ...

  • CAP Accreditation

    PGXL's expanded lab has been accredited by the College of American Pathologists (CAP) after an exacting period of preparation and ...

  • PGXL Software Cleared for Clinical Trials

    PGXL's PerMIT software has received regulatory clearance for a clinical trial involving up to 720 patients. PerMIT:Warfarin is a decision support software ...

  • Entrepreneur of the Year

    Ernst & Young recognizes PGXL's President, Dr. Roland Valdes Jr., as Entrepreneur of the Year. PGXL began as a scientific ...

PGxl Blog

  • DNA-Guided Therapy Is Only Getting Started

    In the New York Times, Dr. Michael C Joyner argues that genetic medicine is disappointing and unworthy of increased research funding. Given ...

  • The Case for Genotyping Before Medicating

    Pediatrics documents the first reported case of opioid intoxication associated with severe respiratory depression in a child taking tramadol. From the ...

  • Pain Management in Hospice Care

    PGXL client ViaQuest is using pharmacogenetics to help manage pain for it's hospice patients. "Knowing which medication is genetically effective for ...

  • The Human Cost of Pain

    It's important, working in a scientifically exciting field like genetics, to remember that everything we do has a human impact. ...